By Iain Gilbert
Date: Wednesday 21 Oct 2026
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration had approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults without cirrhosis, marking the first approval of an antisense oligonucleotide for the disease.
GSK said the drug was cleared under priority review and...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news